Block 5: Convalescent Plasma, Cell Therapy & Apheresis May 19, 2021 3-4:30 EST (2-3:30 CST) 1.5 Contact Hour Recruitment, Collection & Testing of CCP-Blood Center Perspective from the COVID-19 Pandemic Bruce Sachais, MD, PhD Chief Medical Officer & VP, New York Blood Center Enterprises Objectives: 1. Explain what convalescent plasma is and why it is used. 2. Discuss how to build and grow a new program quickly, as exemplified by NYBCs CCP program. 3. Discuss some of the difficulties and challenges that may arise and how to overcome them when building a new program. Level of Instruction: Intermediate Blood Product Utilization During the COVID-19 Pandemic: Transfusion Service Perspective Robert DeSimone, MD, Assistant Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine Objectives: 1. Describe hospital-wide trends in blood product utilization during the pandemic. 2. Review clinical factors associated with need for transfusion in COVID-19 patients. 3. Discuss the important role of randomized clinical trials in the evaluation of convalescent plasma. Level of Instruction: Basic May 26, 2021 3-4:30 EST (2-3:30 CST) 1.5 Contact Hours Overview of Cellular Therapy Joseph (Yossi) Schwartz, MD, Director FACT BOD, Past President, ASFA Objectives: Objectives not available Level of Instruction: Not available June 2, 2021 3-4:30 EST (2-3:30 CST) 1.5 Contact Hours Cellular Therapy Laboratories Rona Singer Weinberg, PhD, Executive Director, Comprehensive Cell Solutions, New York Blood Center Objectives: 1. Define regulatory requirements for manufacturing cellular therapy products. 2. Describe sources for obtaining and methods for processing and cryopreserving hematopoietic and mononuclear cell products. 3. Discuss purity and potency assays used for cellular therapy products. Level of Instruction: Basic Cell Therapy cGMP Yen-Michael S. Hsu, MD, PhD, FCAP, Director of Immunologic Monitoring and Cellular Products Laboratory and Associate Professor of Medicine, UPMC Hillman Cancer Center Objectives: 1. Describe cGMP in cellular therapy practices. 2. Explain why IND is important for enabling cell-based clinical trials using cell products. 3. Discuss the roles of cGMP facility and operation to support clinical trials. Level of Instruction: Intermediate